Lanreotide
Performance & EnduranceLong-acting somatostatin analog similar to octreotide, for acromegaly and neuroendocrine tumors.
Key Benefits
- ✓Treats acromegaly
- ✓Controls NETs
- ✓Reduces GH and IGF-1
- ✓Long-acting convenience
- ✓Similar to octreotide
Dosing Information
Detailed Protocol
Administered via deep subcutaneous injection as depot formulation. Given every 4 weeks (or less frequently in some formulations). Can be self-administered after training.
About Lanreotide
Lanreotide (Somatuline) is a synthetic octapeptide analog of somatostatin with prolonged action. It has similar effects to octreotide but different pharmacokinetics. Available as extended-release depot formulation allowing monthly or extended dosing.
Research Notes
FDA-approved for acromegaly and NETs. Similar efficacy to octreotide with potentially better tolerability. Depot formulation allows less frequent dosing.
Potential Side Effects
- •Injection site reactions
- •GI symptoms
- •Gallstones
- •Bradycardia
- •Hyperglycemia
Always consult with a healthcare professional before starting any peptide therapy.